Silke Thomsen-Bosslet

Title: Silke Thomsen-Bosslet: Innovator in Monoclonal Antibody Production

Introduction

Silke Thomsen-Bosslet is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of three patents to her name, her work focuses on enhancing the immunoreactivity of proteins for medical applications.

Latest Patents

One of her latest patents involves proteins with high immunoreactivity and methods for their production. This invention relates to (glyco-) proteins, specifically monoclonal antibodies, which exhibit an immunoreactivity greater than 81%, and preferably greater than 90%. The innovative monoclonal antibodies are produced using a fluidized bed reactor combined with a conventional protein-chemical purification method or a purification method that minimizes column chromatography. The resulting monoclonal antibodies are suitable for in vivo diagnosis of inflammatory diseases and bone marrow metastases when gamma-irradiated, such as Tc-99m labeled. Additionally, in alpha- or beta-irradiated forms, such as astatine or Re-188 or Y-90 labeled, these antibodies can be utilized in the treatment of leukemia.

Career Highlights

Silke is currently associated with Scintec Diagnostics GmbH, where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, particularly in the area of therapeutic and diagnostic applications of monoclonal antibodies.

Collaborations

Silke collaborates with various professionals in her field, including her coworker Ivan Benes. Their combined expertise contributes to the innovative projects at Scintec Diagnostics GmbH.

Conclusion

Silke Thomsen-Bosslet's contributions to the field of monoclonal antibodies demonstrate her commitment to advancing medical science. Her innovative approaches and successful patents highlight her role as a leading inventor in biotechnology.